Beltsville-based NextCure Inc. (NASDAQ: NXTC), a clinical-stage biopharmaceutical company with one anticancer drug in clinical testing, grossed $86.25 million through its initial public offering of 5.75 million common shares. The 44-employee NextCure priced its IPO at $15 per share and closed Monday at $19.40 per share. It’s been as high as $22.75 on the Nasdaq Global Market since it started trading Thursday. The $86.25 million includes the exercise in full by the underwriters of 750,000 shares. Morgan…
from https://www.bizjournals.com/baltimore/news/2019/05/14/beltsville-biopharmcloses-ipo-grosses-nearly-90m.html?ana=RSS&s=article_search
via https://baltimorecheckbook.tumblr.com/post/184873187632
No comments:
Post a Comment